Tandem Diabetes Care, Inc. Forecast, price target & analysts
Tandem Diabetes Care, Inc. Target price 2025 - Analyst rating & recommendation
Tandem Diabetes Care, Inc. Classifications & Recommendation:
Tandem Diabetes Care, Inc. Price Target
| Target Price | $42.05 |
| Price | $18.89 |
| Potential |
122.61%
register free of charge
|
| Number of Estimates | 20 |
|
20 Analysts have issued a price target Tandem Diabetes Care, Inc. 2026 .
The average Tandem Diabetes Care, Inc. target price is $42.05.
This is
122.61%
register free of charge
$75.00
297.04%
register free of charge
$18.00
4.71%
register free of charge
|
|
| A rating was issued by 24 analysts: 13 Analysts recommend Tandem Diabetes Care, Inc. to buy, 10 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Tandem Diabetes Care, Inc. stock has an average upside potential 2026 of
122.61%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 940.20 | 1,000.73 |
| 25.74% | 6.44% | |
| EBITDA Margin | -8.78% | 2.98% |
| 52.71% | 133.95% | |
| Net Margin | -10.36% | -8.42% |
| 65.92% | 18.72% |
21 Analysts have issued a sales forecast Tandem Diabetes Care, Inc. 2025 . The average Tandem Diabetes Care, Inc. sales estimate is
This results in the following potential growth metrics:
17 Analysts have issued an Tandem Diabetes Care, Inc. EBITDA forecast 2025. The average Tandem Diabetes Care, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
17 Tandem Diabetes Care, Inc. Analysts have issued a net profit forecast 2025. The average Tandem Diabetes Care, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.47 | -1.27 |
| 57.14% | 13.61% | |
| P/E | negative | |
| EV/Sales | 1.29 |
17 Analysts have issued a Tandem Diabetes Care, Inc. forecast for earnings per share. The average Tandem Diabetes Care, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Tandem Diabetes Care, Inc....
Current Tandem Diabetes Care, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
| Baird |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Mar 05 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Mar 04 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Feb 27 2025 |
|
Locked
Baird:
Locked
➜
Locked
|
Feb 27 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
